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Background: Hepatitis E virus (HEV) infection is known to cause
severe liver disease in pregnant women. It is unclear whether ob-
stetric and fetal outcomes are worse in pregnant women with HEV
infection than in women with other forms of viral hepatitis.
Objective: To compare maternal, obstetric, and fetal outcomes in
pregnant women with acute viral hepatitis caused by HEV and
other hepatitis viruses.
Design: Observational cohort.
Setting: Tertiary care hospital, New Delhi, India.
Patients: 220 consecutive pregnant women presenting with jaun-
dice caused by acute viral hepatitis.
Measurements: Maternal mortality and medical complications, ob-
stetric complications, deliveries, and fetal outcomes.
Results: Infection with HEV caused acute viral hepatitis in 60% of
included women. Fulminant hepatic failure was more common (rel-
ative risk, 2.7 [95% CI, 1.7 to 4.2]; P  0.001) and maternal
mortality was greater (relative risk, 6.0 [CI, 2.7 to 13.3]; P 0.001)
in HEV-infected women than in non–HEV-infected women.
Women with HEV infection were more likely than those with
other forms of viral hepatitis to have obstetric complications
(relative risk, 4.1 [CI, 1.7 to 10.2] for antepartum hemorrhage
and 1.9 [CI, 1.3 to 2.7] for intrauterine fetal death; P  0.001
for both) and poor fetal outcomes (relative risk, 1.2 [CI, 1.0 to
1.4] for preterm delivery [P  0.005] and 1.8 [CI, 1.2 to 2.5] for
stillbirth [P  0.026]).
Limitations: The findings may not apply to community settings, to
women who are asymptomatic or have only minor symptoms, or in
the setting of an HEV epidemic.
Conclusions: Pregnant women with jaundice and acute viral hep-
atitis caused by HEV infection had a higher maternal mortality rate
and worse obstetric and fetal outcomes than did pregnant women
with jaundice and acute viral hepatitis caused by other types of viral
hepatitis.
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Hepatitis E virus (HEV) is a single-stranded RNA virusthat causes large-scale epidemics and sporadic cases of
acute viral hepatitis in developing countries (1, 2). Infec-
tion with HEV also poses a significant risk for acute viral
hepatitis to travelers in endemic areas (3). The main source
of transmission of HEV is contaminated drinking water (4,
5). In men and nonpregnant women, the disease is usually
self-limited and has a low case-fatality rate (0.1%) (6).
However in pregnant women, HEV infection is more se-
vere, often leading to fulminant hepatic failure and death
in up to 15% to 20% of cases. This high mortality rate was
first reported in an epidemic setting in the early 1980s (7)
and was reported again in a sporadic setting in 2003 (8).
Information is limited and conflicting on the effect of
HEV infection on maternal, obstetric, and fetal outcomes
(9, 10). Therefore, we describe the prevalence and clinical
outcomes of acute viral hepatitis in a series of HEV-
infected pregnant women and compare their maternal, ob-
stetric, and fetal outcomes with those of pregnant women
without HEV infection.
METHODS
Setting and Participants
The study was conducted at the Department of Ob-
stetrics and Gynecology, Lady Hardinge Medical College,
and Shrimati Sucheta Kriplani Hospital, New Delhi, India
(a large tertiary care hospital), in collaboration with the
Department of Gastroenterology, G.B. Pant Hospital,
New Delhi. Consecutive pregnant women at any gesta-
tional stage who presented between January 2003 and July
2005 with acute viral hepatitis were systematically assessed
for hepatitis virus infection by using liver function tests
and serologic analysis. Acute viral hepatitis was diagnosed
(7) by a serum bilirubin level of 34 mol/L or greater (2
mg/dL); a serum alanine aminotransferase level 2.5 times
the upper limit of normal or greater; and positivity for any
hepatotropic virus by using the following serologic tests:
hepatitis B surface antigen; antibody to hepatitis C virus;
and IgM antibodies to hepatitis A virus, hepatitis B core
antigen, hepatitis delta virus, and HEV. We excluded pa-
tients with negative results on viral serologic examination,
those with dual viral infection, those with clinical evidence
of other causes of jaundice (such as biliary obstruction, the
HELLP syndrome [hemolytic anemia, elevated liver en-
zyme level, low platelet count], acute fatty liver of preg-
nancy, hemolytic jaundice, and drug-induced jaundice),
See also:
Print
Editors’ Notes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
Web-Only
Appendix Table
Conversion of tables into slides
Annals of Internal MedicineArticle
28 © 2007 American College of Physicians
and those with clinical or laboratory evidence of chronic
liver disease.
Women who met the case definition of acute viral
hepatitis were managed in a separate hepatitis hospital
ward. Management depended on whether the patient’s
acute viral hepatitis was complicated by fulminant hepatic
failure, which was diagnosed when hepatic encephalopathy
developed in a patient with acute viral hepatitis within 4
weeks of the onset of jaundice (11).
Patients without fulminant hepatic failure were
given standard care and were monitored for signs and com-
plications of acute viral hepatitis (fever, edema, ascites,
paralytic ileus, nasal and gastrointestinal hemorrhage, high
leukocyte count, high creatinine concentration, hepatic en-
cephalopathy, clinically significant coagulation defect [in-
ternational normalized ratio 2.0], hypoglycemia, hypo-
natremia, hypernatremia, hypokalemia, hyperkalemia, and
hypocalcemia), and obstetric complications (antepartum,
intrapartum, or postpartum hemorrhage; premature rupture
of membranes; and intrauterine death). If their condition im-
proved, patients were discharged and instructed to return for
regular outpatient follow-up visits until delivery.
Patients with fulminant hepatic failure were managed
with supportive care in the intensive care unit because liver
transplantation facilities are not available in the hospital.
They were monitored for increased intracranial tension
along with other medical and obstetric complications.
They received 20% mannitol, lactulose, antibiotics, paren-
teral nutrition, and ventilatory support, as needed. Women
without fulminant hepatic failure who had fetal distress,
meconium staining of amniotic fluid, no progress of labor,
or obstructed labor underwent cesarian section. Termina-
tion of pregnancy was considered in cases of intrauterine
death, severe intrauterine growth retardation, a nonreactive
non–stress test result, postdated pregnancy, and premature
rupture of membrane at term only if the patient had im-
proving liver function and a coagulation profile that could
be further corrected by giving fresh frozen plasma. Termi-
nation of pregnancy was not considered for women with
fulminant hepatic failure. All women with manifestations
of bleeding were infused with fresh frozen plasma and
packed red cells.
In keeping with the policy of our institutions, the
study did not require institutional review board approval
or documented informed consent from patients for study
participation because patients received care according to a
standard clinical protocol, their care was not influenced by
their inclusion in the study, and data were collected and
recorded according to ethical standards and norms in India
and were analyzed with total anonymity of patients.
Statistical Analysis
We used the t test and the Mann–Whitney U test to
compare normally distributed data and non-normally dis-
tributed data, respectively, of HEV-infected and non–
HEV-infected patients. The chi-square test was used to
compare discrete values between groups. A P value less
than 0.05 was considered significant. Relative risk was cal-
culated for all complications in HEV-infected pregnant
women versus non–HEV-infected pregnant women. Statis-
tical analyses were done by using SPSS, version 13.0
(SPSS, Chicago, Illinois).
Role of the Funding Source
The study received no external funding.
RESULTS
Patients
Of the 33 385 pregnant women who were admitted
during the study period, 316 (0.9%) presented with jaun-
dice. Ninety-two were excluded for causes of jaundice
other than viral hepatitis (intrahepatic cholestasis of preg-
nancy [41 women], the HELLP syndrome [6 women],
acute fatty liver of pregnancy [3 women], drug hepatotox-
icity [7 women], hemolytic jaundice [14 women], chole-
docholithiasis [6 women], and unknown cause [15 women]),
and 4 were excluded for dual viral infection. The remain-
ing 220 pregnant women with jaundice met the inclusion
criteria for acute viral hepatitis. None had evidence of
autoimmune disease.
Table 1 shows patient characteristics. The mean ma-
ternal age was 22.4 years (SD, 3.2). Sixty-one women
(28%) were in the second trimester of pregnancy (mean
gestational age, 26.2 weeks [SD, 2.0]) and 159 (72%) were
in the third trimester (mean gestational age, 34.2 weeks
[SD, 2.6]). The mean duration of jaundice before hospi-
talization was 4.9 days (SD, 2).
Context
Hepatitis E virus (HEV) infection causes severe liver disease
in pregnant women.
Contribution
In a case series of 220 pregnant women with jaundice and
acute viral hepatitis, the authors observed that women
with HEV infection more often died and had more obstet-
ric complications and worse fetal outcomes than did
women with other forms of viral hepatitis.
Caution
The series was restricted to symptomatic women at a
referral center.
Implication
Infection with HEV not only causes more severe liver dis-
ease in pregnant women but also appears to contribute to
worse obstetric and fetal outcomes compared with other
forms of viral hepatitis.
—The Editors
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Cause of Hepatitis
Infection with HEV was the most common cause of
acute viral hepatitis (132 participants [60%]) (Table 1).
Hepatitis B virus (HBV) infection was the most common
cause of non–HEV acute viral hepatitis (72 participants
[33%]). Fewer HEV-infected patients than non–HEV-
infected patients were in their third trimester of pregnancy,
corresponding to a lower mean gestational age for HEV-
infected patients (31 weeks [SD, 4.1] vs. 33 weeks [SD,
4.4]; P  0.004) (Table 1). The median duration of jaun-
dice did not differ between HEV-infected women and
non–HEV-infected women (4 days [range, 1 to 15 days]
vs. 4.5 days [range, 2 to 10 days]; P  0.68).
Fulminant Hepatic Failure
Ninety-one women (41%) had fulminant hepatic fail-
ure, of whom 54 (59%) had fulminant hepatic failure on
admission and 37 (41%) developed fulminant hepatic fail-
ure during hospitalization. Fulminant hepatic failure was
more common among HEV-infected women than non–
HEV-infected women (73 of 132 [55%] vs. 18 of 88
[20%]; relative risk, 2.7 [CI, 1.7 to 4.2]; P  0.001) (Ta-
ble 1) and among HEV-infected women in their third
trimester (46 of 88 [52%] vs. 11 of 71 [15%] noninfected
women; relative risk, 3.4 [CI, 1.9 to 6.0]; P  0.001). The
frequency of fulminant hepatic failure did not statistically
significantly differ between HEV-infected women and
non–HEV-infected women in their second trimester (27 of
44 [61%] vs. 7 of 17 [41%]; P  0.26).
Jaundice before hospital admission was of longer du-
ration in women with fulminant hepatic failure than in
those without fulminant hepatic failure (5.4 days [SD, 2.6]
vs. 4.6 days [SD, 1.5]; P  0.010). In women who devel-
oped fulminant hepatic failure, the mean interval from on-
set of jaundice to onset of encephalopathy was 108 hours
(SD, 58) and was similar in HEV-infected and non–HEV-
infected women (112 hours [SD, 60] vs. 93 hours [SD,
50]; P  0.18). The mean duration of encephalopathy be-
fore admission was 20 hours (SD, 15) and was similar in
HEV-infected and non–HEV-infected women.
Maternal Mortality and Complications of Infection
Maternal mortality was higher in HEV-infected
women and occurred exclusively in women with fulminant
hepatic failure (Table 2). Signs and complications of infec-
tion that differed by HEV status were an international
normalized ratio greater than 2.0, nasal or gastrointestinal
hemorrhage, leukocyte count of 11 109 cells/L or
greater, high serum creatinine concentration (34 mol/L
[2 mg/dL]), ascites, and signs of increased intracranial
tension. Differences between groups in other clinical and
laboratory features, and complications did not reach statis-
tical significance (data not shown).
Obstetric Complications
Antepartum hemorrhage and intrauterine fetal death
were more frequent in HEV-infected women than in non–
HEV infected women, whereas rates of postpartum hem-
orrhage and premature rupture of membranes did not dif-
fer between groups (Table 3).
Table 1. Patient Characteristics*
Variable HEV-Infected Women
(n  132)
Non–HEV-Infected Women
(n  88)
P Value
Mean age (SD), y 22.2 (3.4) 22.5 (3.0) 0.54
Median gravida (range), n 2 (1–6) 2 (1–7) 0.96
Mean gestational age (SD), wk 31 (4.1) 33 (4.4) 0.004
Trimester, n (%) 0.023
Second 44 (33) 17 (19)
Third 88 (67) 71 (81)
Socioeconomic status, n (%)† 0.29
Middle 58 (44) 45 (51)
Low 74 (56) 43 (49)
Median duration of jaundice before admission (range), d 4 (1–15) 4.5 (2–10) 0.68
Acute viral hepatitis, n (%) 0.001
With fulminant hepatic failure 73 (55) 18 (20)
Without fulminant hepatic failure 59 (45) 70 (80)
Laboratory data
Mean hemoglobin level (SD), g/L 84 (14) 88 (12) 0.026
Median leukocyte count (range), cells  109/L 12 (4–33) 9.5 (4–28) 0.001
Mean platelet count (SD), cells  109/L 211.3 (59.6) 238.2 (56.4) 0.001
Mean serum bilirubin level (SD) 0.001
mol/L 255.0 (90.1) 181.9 (86.7)
mg/dL 15.0 (5.3) 10.7 (5.1)
Median alanine aminotransferase level (range), U/L 90.5 (24.8–310.1) 54.5 (10.0–212.2) 0.001
Median prothrombin time (range), s‡ 58 (15–150) 19 (15–105) 0.001
Median international normalized ratio (range) 4.0 (1.0–18.6) 1.6 (1.0–7.1) 0.001
Mean serum albumin level (SD), g/L 36 (10) 42 (9) 0.001
* HEV  hepatitis E virus.
† Based on reference 12.
‡ Control value, 15 seconds.
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Deliveries
The median interval between admission and delivery
was 24 hours (range, 1 to 312 hours) in HEV-infected
women and 18 hours (range, 6 to 168 hours) in non–
HEV-infected women (P  0.01). Of 186 deliveries, 89
patients (41%) were in labor at the time of admission and
97 (44%) went into labor after admission; 156 deliveries
(84%) were preterm (gestational age 37 weeks) and 30
(16%) were full term (gestational age 37 weeks). Preterm
deliveries were more common in HEV-infected women,
and full-term deliveries were more common in non–HEV-
infected women. Seven women had cesarean section. No
patient with fulminant hepatic failure was induced.
Of the 34 women (15%) who did not deliver while
hospitalized, 14 were discharged uneventfully and gave
birth to healthy babies. The remaining 20 women died in
the hospital before delivery; 19 of these women had HEV
infection (Table 3).
Fetal Outcomes
Pregnant women who were infected with HEV had
fewer live births and more stillbirths than non–HEV-
infected women (Table 3). The number of spontaneous
abortions or neonatal deaths did not differ between the
groups. Of 30 neonatal deaths, 28 (93%) were preterm,
and 17 of the 28 preterm deaths (61%) occurred in HEV-
infected women.
Seventy women with fulminant hepatic failure and
116 women without fulminant hepatic failure delivered.
Only 2 of the 70 deliveries (3%) in women with fulminant
hepatic failure were live births (2 of 53 deliveries [4%] in
HEV-infected women vs. 0 of 17 deliveries [0%] in non–
HEV-infected women; P  1.0). Both women with fulmi-
nant hepatic failure who had live births were infected with
HEV. One child survived and 1 died (neonatal death).
Of the 116 deliveries in women without fulminant
hepatic failure, significantly fewer live births were among
HEV-infected women than non–HEV-infected women
(20 of 52 [38%] vs. 40 of 64 [62%]; P  0.009). Among
the 28 women without fulminant hepatic failure who de-
livered live babies at full term, live births were less com-
mon in HEV-infected women than non–HEV-infected
women (5 of 8 [62%] vs. 19 of 20 [95%]; P  0.026).
DISCUSSION
In this prospective study of 33 385 pregnant women
admitted to a New Delhi hospital, we found that 220
(0.6%) had jaundice caused by acute viral hepatitis and
that HEV infection accounted for 60% of these cases. Ful-
minant hepatic failure was more common in HEV-infected
women, and more HEV-infected women died, had obstet-
ric complications, or had worse fetal outcomes than did
women who had jaundice and acute viral hepatitis caused
by other hepatitis viruses.
The Appendix Table (available at www.annals.org)
summarizes results of other studies. Our observation that
HEV infection causes 60% of cases of jaundice and acute
viral hepatitis among pregnant women is consistent with
those of 2 other studies. Jaiswal and colleagues (13) in
central India and Aziz and associates (14) in Pakistan re-
ported that HEV is responsible for 58% and 62% of cases
of acute viral hepatitis in pregnant women, respectively.
Two studies from New Delhi (15, 16) reported slightly
lower prevalences (45% and 37%), and a study of sporadic
HEV infection in the context of multiple HEV epidemics
in Kashmir reported a prevalence of 86% among pregnant
patients with acute viral hepatitis (8). These differences in
estimates may be due to the small samples and regional
differences in HEV prevalence.
Our observation that a high proportion of HEV-
infected pregnant women develop fulminant hepatic fail-
ure has been previously recognized. In a 1981 report of
epidemic HEV infection, 22% of pregnant women with
acute viral hepatitis developed fulminant hepatic failure,
compared with 0% of nonpregnant women and 2.8% of
Table 2. Maternal Mortality and Medical Complications*
Variable HEV-Infected Women
(n  132), n/n (%)
Non–HEV-Infected Women
(n  88), n/n (%)
Relative Risk
(95% CI)
P Value
Maternal mortality rate
Overall 54/132 (41) 6/88 (7) 6.0 (2.7–13.3) 0.001
Patients with fulminant hepatic failure 54/73 (74) 6/18 (33) 2.2 (1.1–4.3) 0.001
Second trimester 18/27 (66) 0/7 (0) – 0.002
Third trimester 36/46 (78) 6/11 (54) 1.4 (0.8–2.5) 0.11
Patients without fulminant hepatic failure 0/59 (0) 0/70 (0) – 1.00
Medical complications
Coagulation defect† 104/132 (79) 32/88 (36) 2.2 (1.6–2.9) 0.001
Nasal or gastrointestinal hemorrhage 25/132 (19) 4/88 (4) 4.2 (1.5–11.6) 0.002
Leukocyte count 11  109 cells/L 86/132 (65) 31/88 (35) 1.8 (1.4–2.5) 0.001
Serum creatinine concentration 34 mol/L (2 mg/dL) 39/132 (30) 4/88 (4) 6.5 (2.4–17.5) 0.001
Ascites 33/132 (25) 5/88 (6) 4.4 (1.8–10.8) 0.001
Clinical signs of increased intracranial tension 27/132 (20) 1/88 (1) 18.0 (2.5–130.1) 0.001
* HEV  hepatitis E virus.
† International normalized ratio 2.0.
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men (7). Other studies documented the development of
fulminant hepatic failure in 32% to 69% of HEV-infected
pregnant women with acute viral hepatitis in sporadic set-
tings (8, 13, 15, 16).
The reasons for the high frequency of fulminant he-
patic failure are unclear and are being researched. A shift in
TH1–TH2 balance toward a TH2 response in pregnant
women with HEV infection but not in nonpregnant
women with HEV infection (17) may point toward a pri-
mary immunologic cause of severe disease in pregnancy. In
addition, hormones of pregnancy, especially estrogen and
progesterone, might impair cellular immunity by triggering
adapter protein (ORF3 of HEV), which could facilitate
viral replication and lead to release of cytokines and liver
cell apoptosis (18, 19).
Obstetric and fetal outcomes in pregnant women with
acute viral hepatitis have not been adequately studied. Of
186 deliveries in our study, 84% were preterm, and a sig-
nificantly higher proportion of preterm deliveries occurred
in HEV-infected women. Only 1 study reported a high
frequency of preterm delivery in HEV-infected pregnant
women (67%) (15).
To our knowledge, our observation that HEV-infected
pregnant women had worse fetal outcomes has not been
previously reported. The mechanism underlying these out-
comes is not known, but vertical transmission might be a
cause. In 1 study, vertical transmission of HEV was de-
tected in 5 newborns whose mothers had developed hepa-
titis during an epidemic of waterborne HEV infection
(20). Vertical transmission was also detected in 26 cases of
HEV RNA–positive women by testing for HEV RNA in
cord blood or newborn blood (21), although the possibility
of contamination of cord blood with the maternal blood
could not be excluded.
Our study has several limitations. Our hospital is a
tertiary care center, and the relatively high frequency of
acute viral hepatitis in pregnancy and of fulminant hepatic
failure in women with acute viral hepatitis might be ex-
plained in part by referral bias. In addition, the fact that
many women with HBV hepatitis are referred to our hos-
pital in their third trimester for HBV immunoglobulin
therapy may influence comparisons between HEV-infected
women and non–HEV-infected women, because HBV-
infected women form a major portion of non–HEV-in-
fected groups. However, our findings for non–HEV-
infected women are consistent with those of other studies
from the region (13, 14, 16). In addition, whether cases of
HBV hepatitis were due to acute HBV infection or reacti-
vation of chronic HBV infection in pregnancy remains to
be determined. We studied hospitalized women who pre-
sented with symptoms and signs of acute viral hepatitis.
Thus, our findings do not apply to the many patients who
were asymptomatic or had only minor symptoms and were
seen as outpatients. Our observations were made in the
Table 3. Obstetric Complications and Fetal Outcomes*
Variable HEV-Infected Women
(n  132), n/n (%)
Non–HEV-Infected Women
(n  88), n/n (%)
Relative Risk
(95% CI)
P Value
Obstetric complications
Antepartum hemorrhage 31/132 (23) 5/88 (6) 4.1 (1.7–10.2) 0.001
Second trimester 15/44 (34) 0/17 (0) – 0.006
Third trimester 16/88 (18) 5/71 (7) 2.6 (1.0–6.7) 0.039
Postpartum hemorrhage 18/132 (14) 8/88 (9) 1.5 (0.7–3.3) 0.31
Second trimester 5/44 (11) 2/17 (12) 1.0 (0.2–4.5) 0.96
Third trimester 13/88 (15) 6/71 (8) 1.7 (0.7–4.4) 0.22
Premature rupture of membranes 12/132 (9) 3/88 (3) 2.7 (0.8–9.2) 0.10
Second trimester 5/44 (11) 0/17 (0) – 0.15
Third trimester 7/88 (8) 3/71 (4) 1.9 (0.5–7.0) 0.34
Intrauterine fetal deaths 77/132 (58) 27/88 (31) 1.9 (1.3–2.7) 0.001
Second trimester 33/44 (75) 10/17 (59) 1.3 (0.8–2.0) 0.21
Third trimester 44/88 (50) 17/71 (24) 2.1 (1.3–3.3) 0.001
Fetal outcomes†
Preterm delivery 95/105 (90) 61/81 (75) 1.2 (1.0–1.4) 0.005
Poor fetal outcome 83/105 (79) 41/81 (51) 1.6 (1.2–2.0) 0.001
Second trimester 33/33 (100) 14/15 (93) – 0.68
Third trimester 50/72 (69) 27/66 (41) 1.7 (1.2–2.4) 0.001
Spontaneous abortions 8/105 (8) 4/81 (3) 1.5 (0.5–4.9) 0.68
Stillbirths 57/105 (54) 25/81 (1) 1.8 (1.2–2.5) 0.026
Neonatal deaths 18/105 (17) 12/81 (15) 1.2 (0.6–2.3) 1.00
Live births (in hospital) 22/105 (21) 40/81 (49) 0.4 (0.3–0.6) 0.001
Second trimester 0/33 (0) 1/15 (7) – 0.68
Third trimester 22/72 (31) 39/66 (59) 0.5 (0.3–0.8) 0.001
Other maternal outcomes
Recovered and discharged from hospital before
delivery and had live birth on follow-up
8/132 (6) 6/88 (7) 0.9 (0.3–2.5) 0.82
Died in hospital before delivery 19/132 (14) 1/88 (1) 12.7 (1.7–92.9) 0.001
* HEV  hepatitis E virus.
† Among 186 deliveries. The few fetal losses that occurred during delivery are counted as stillbirths, not as intrauterine fetal deaths.
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setting of sporadic transmission of HEV and cannot be
generalized to an epidemic setting. Our data may have
limited applicability in settings in which orthotopic liver
transplantation is readily accessible, although availability of
the procedure would be unlikely to alter obstetric or fetal
outcomes.
In summary, in a prospective series of 220 pregnant
women with jaundice and acute viral hepatitis, HEV infec-
tion caused 60% of cases and was associated with an in-
crease in maternal mortality, obstetric complications, and
poor fetal outcomes. Further research is warranted to de-
termine how best to prevent these adverse outcomes.
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Appendix Table. Studies of Hepatitis E Virus Infection in Pregnancy
Study, Year (Reference) Patients, n Prevalence of Hepatitis E
Virus Infection, %
Patients with Fulminant
Hepatic Failure, %
Mortality
Rate, %
Medhat et al., 1993 (22) 55 30 43 100
Tsega et al., 1993 (23) 32 59 – 42
Jaiswal et al., 2001 (13) 127 58 58 45
Singh et al., 2003 (16) 60 37 64 64
Khuroo and Kamili, 2003 (8) 76 86 69 55
Strand et al., 2003 (24) 20 40 – 30
Kumar et al., 2004 (15) 65 45 32 73
Present study, 2007 220 60 55 41
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